| Opportunity ID: |
310152 |
| Opportunity Number: |
NOT-TR-19-007 |
| Opportunity Title: |
Notice of Intent to Publish a Funding Opportunity Announcement for Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Grant |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.350 |
| Eligible Applicants: |
State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: |
|
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Nov 05, 2018 |
| Last Updated Date: |
Nov 05, 2018 |
| Estimated Synopsis Post Date: |
Dec 01, 2018 |
| Fiscal Year: |
2019 |
| Award Ceiling: |
|
| Award Floor: |
|
| Estimated Total Program Funding: |
$5,000,000 |
| Expected Number of Awards: |
4 |
| Description: |
The National Center for Advancing Translational Sciences (NCATS), as part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative, intend to publish a Funding Opportunity Announcement (FOA) to create and test devices that can model the mechanisms or effects of nociception/pain-relevant signaling, addiction, or opioid use disorders (OUDs), using human tissues in in vitro microphysiological systems (MPS), also known as “tissue chips” or “organs-on-chip”. The FOA will invite applications for development and validation of highly reproducible and translatable in vitro MPS models that can be utilized for preclinical efficacy studies by providing information on the discovery and validation of translatable biomarkers, development of standardized methods for preclinical efficacy testing, and definitive efficacy testing of candidate therapeutics using best practices and rigorous study design. An essential feature of funded projects will be a multidisciplinary approach that brings together experts in pain and opioid use disorders (OUD), bioengineering, microfluidics, material science, "omic" sciences, computational biology, disease biology, pathology, electrophysiology, pharmacology, biostatistics and clinical science. Partnerships between MPS developers and relevant pain/OUD disorder (which includes addiction, tolerance, withdrawal and overdose) experts, plus clinical researchers and/or patient cohorts (if applicable) will be essential. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in December 2018, with an expected application due date in February 2019. This FOA will utilize the UG3/UH3 activity code, which supports a bi-phasic Cooperative Agreement to support innovative exploratory and development research activities with substantial involvement from NIH program staff. Details of the planned FOA are provided below. |
| Version: |
1 |
|
